Skip to main content
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Subscribe
Home
Issues
2023
June 2023 - Vol 16 No 1
2022
December - Vol 15 No 4
September - Vol 15 No 3
June - Vol 15 No 2
March - Vol 15 No 1 - Online Only
Issue Archive
Special Issues
December 2023 Vol 16, Payers' Guide to FDA Updates
Supplements
Special Issue Archive
Topics
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
Web Exclusives
Web Exclusive Topics
All Web Exclusives
Select Drug Profiles
FDA Approvals
In the News
Press Releases
Videos
Interview with the Innovators
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Reprints
Conference Highlights ASH
Conference Highlights ASH
A Multicenter, Phase 4 Observational Study of Ofatumumab in Chronic Lymphocytic Leukemia: A European Research Initiative on CLL (ERIC) Study
Play Video
Conference Highlights ASH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib and Rituximab for Previously Treated Patients with Chronic Lymphocytic Leukemia
Play Video
Conference Highlights ASH
Advances in Cellular Therapies for Hematologic Malignancies Highlighted at ASH 2019
Wayne Kuznar
Wayne Kuznar
Play Video
Conference Highlights ASH
American Society of Hypertension Highlights
Play Video
Conference Highlights ASH
Chemoimmunotherapy with Fludarabine, Cyclophosphamide, and Rituximab versus Bendamustine and Rituximab in Previously Untreated and Physically Fit Patients with Advanced Chronic Lymphocytic Leukemia
Play Video
Conference Highlights ASH
Chronic Lymphocytic Leukemia: A New Treatment Era is Born
Play Video
Conference Highlights ASH
Combination Biologic Therapy Without Chemotherapy as Initial Treatment for Mantle-Cell Lymphoma: Multicenter Phase 2 Study of Lenalidomide Plus Rituximab
Play Video
Conference Highlights ASH
DVT Prophylaxis: First Comparison of Catheter- Directed Thrombolysis versus Standard Care
Neil Canavan
,
Neil Canavan
Play Video
Conference Highlights ASH
Favorable Data for Ruxolitinib and for a New JAK Inhibitor in Myelofibrosis
Neil Canavan
,
Neil Canavan
Play Video
Conference Highlights ASH
Genetic Profiles Linked to Hematologic Outcomes
Caroline Helwick
,
Caroline Helwick
Play Video
1
2
3
4
Page 1 of 4
Results 1 - 10 of 35